EN | RU
EN | RU

Help Support

Back

Intramuscular calcitonin has better efficacy than oral celecoxib to treat knee bone marrow lesions

Intramuscular calcitonin has better efficacy than oral celecoxib to treat knee bone marrow lesions Intramuscular calcitonin has better efficacy than oral celecoxib to treat knee bone marrow lesions
Intramuscular calcitonin has better efficacy than oral celecoxib to treat knee bone marrow lesions Intramuscular calcitonin has better efficacy than oral celecoxib to treat knee bone marrow lesions

The retrospective study aimed to compare the short-term clinical effect of intramuscular calcitonin with oral celecoxib in treating patients with knee BMLs.

See All

Key take away

The study comparing intramuscular calcitonin with oral celecoxib in 123 knee BML patients depicted that intramuscular calcitonin 50 IU once daily illustrated a better short-term effect in comparison with oral celecoxib 200 mg twice per day. 

Background

The retrospective study aimed to compare the short-term clinical effect of intramuscular calcitonin with oral celecoxib in treating patients with knee BMLs.

Method

The medical records of patients with knee BMLs treated by intramuscular calcitonin or oral celecoxib were reviewed between January 2016 and December 2018. The study recruited 123 patients. Participants were randomized to receive calcitonin treatment (n = 66) or celecoxib treatment (n = 57). For 3 months, all the subjects were followed up radiographically and clinically. 

To assess knee pain and function, VAS (Visual analog scale) and the WOMAC (Western Ontario and McMaster University Osteoarthritis Index) were respectively used. BMLs were assessed by MRI (magnetic resonance imaging) scans and were scored by the modified WORMS (Whole-Organ MRI Score). The safety assessment of these two medications was also done.

Result

In the calcitonin group, the VAS and WOMAC scores were lower statistically than celecoxib group at 4-week and 3-month follow-up. The comparison of clinical outcomes between the two groups is depicted in the following table:


For BMLs, the WORMS scores in the calcitonin group were remarkably lower than the celecoxib group. The BMLs scores changed between the two groups are depicted in the following table:


Furthermore, statistically higher MRI improvement rates were found in the calcitonin group compared with the celecoxib group at 4-week follow-up (21.21% vs. 7.01%) and 3-month follow-up (37.88% vs. 15.79%). The percentage of patients with improved BMLs is depicted in the following table:

Conclusion

Compared with celecoxib, intramuscular calcitonin provides a greater short-term clinical efficacy in the treatment of knee BMLs patients.

Source:

Journal of Orthopaedic Surgery and Research

Article:

Clinical effect of intramuscular calcitonin compared with oral celecoxib in the treatment of knee bone marrow lesions: a retrospective study

Authors:

Jiaming Zhou et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: